Claims
- 1. A method of treating a viral condition caused by an enveloped virus, said method comprising using a therapeutically effective amount of a compound selected from the group consisting of a substituted benzene, wherein said benzene comprises a 2-R.sup.1, 3-R.sup.2 -1-OX.sup.1, 4-OX.sup.2 compound where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring and OX.sup.1 and OX.sup.2 are simultaneously hydroxy.
- 2. The method of claim 1 wherein said virus is influenza, subclass A.
- 3. The method of claim 1 wherein said virus is influenza, subclass B.
- 4. The method of claim 1 wherein said virus is influenza, subclass C.
- 5. The method of claim 1 wherein R.sup.1 is a hydrocarbon moiety of one to ten carbons.
- 6. The method of claim 1 wherein R.sup.2 is a hydrocarbon moiety of one to ten carbons.
- 7. The method of claim 1 wherein R.sup.1 is --CH.sub.2 --O--R.sup.3 and R.sup.3 is a hydrocarbon moiety of one to ten carbons.
- 8. The method of claim 1 wherein R.sup.1 is tert-butyl and R.sup.2 is hydrogen.
- 9. The method of claim 1 wherein one hydrogen of one hydroxyl of said diol is substituted with a hydrocarbon moiety of one to six carbons.
- 10. The method of claim 1 further comprising preventing said viral condition using a therapeutically effective amount of said compound.
- 11. A method of treating a viral condition caused by an enveloped virus, said method comprising using a therapeutically effective amount of a compound having an IC.sub.50 of less than 10.sup.-3 M in the INF assay, wherein said compound comprises a substituted benzene, wherein said benzene comprises a 2-R.sup.1, 3-R.sup.2 -1-OX.sup.1, 4-OX.sup.2 compound where at least one of R.sup.1 and R.sup.2 include a CH.sub.2 linkage to the benzene ring and OX.sup.1 and OX.sup.2 are simultaneously hydroxy.
- 12. The method of claim 11 further comprising preventing said viral condition using a therapeutically effective amount of said compound.
- 13. A method of treating a viral condition caused by an enveloped virus, said method comprising using a therapeutically effective amount of tert-butylhydroquinone.
- 14. The method of claim 13 wherein said viral condition is influenza.
- 15. A method of treating a viral condition caused by an enveloped virus, said method comprising using a therapeutically effective amount of a compound which binds near the hinge region or near the stem region of hemagglutinin.
- 16. The method of claim 15 wherein said compound binds near the region of Asn 296A; Tyr 308A, Val 309A, Lys 310A, Gln 311A, Asn 312A, Glu 85B, Asp 86B, Thr 87B, Lys 88B, Ile 89B, Asp 90B, Leu 91B, Trp 92B, Ser93B, Try 94B, Asn 95B, Ala 96B, Glu 97B, Leu 98B, Leu 99B, Pro 293C, Phe 294C, Gln 295C, Gly 303C, Ala 304C, Cys 305C, Pro 306C, Lys 307C, Tyr 308C, Val 309C, Lys 58D, Thr 59D, Asn 60D, Glu 61D, Lys 62D, Thr 87D, Lys 88D, Ile 89D, Asp 90D, Leu 91D, Trp 92D, Ser 93D, Tyr 94D, Asn 95D, Ala 96D and Leu 99D.
- 17. The method of claim 15 wherein said compound binds near the region of Cys14A, Leu 15A, Gly 16A, His 18A, Glu 325A, Ile 10B, Glu 11B, Asn 12B, Gly 13B, Trp 14B, Arg 25B, Asn 135B, and Cys 137B.
- 18. A method of treating a viral condition wherein the viral condition is caused by a virus having a fusion protein which has a native, non-fusogenic conformation and a second, fusogenic conformation, the method comprising using a therapeutically effective amount of a compound which binds to the fusion protein in the native conformation and reduces the ability of the fusion protein to adopt the fusogenic conformation.
- 19. The method of claim 18 wherein said compound is selected from the group consisting of a substituted benzene, wherein said benzene comprises a 2-R.sup.1, 3-R.sup.2 -1-OX.sup.1, 4-OX.sup.2 compound where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring and OX.sup.1 and OX.sup.2 are simultaneously hydroxy.
- 20. The method of claim 18 wherein said compound comprises tert-butylhydroquinone.
- 21. The method of claim 18 wherein said viral condition is caused by a virus from a family in the group consisting of Togaviridae, Flaviviridae, Coronaviridae, Rhabdoviridae, Filoviridae, Paramyxoviridae, Orthomyxoviridae, Bunyaviridae, Arenaviridae, Retroviridae, Hepadnaviridae, Herpesviridae, Poxviridae and Iridoviridae.
- 22. The method of claim 18 wherein said viral condition is caused by a virus in the group consisting of rubella, yellow fever, rabies, influenza, Korean hemorrhagic fever, common colds, respiratory syncytial virus, measles, mumps, HIV, hepatitis B, Herpes simplex, CMV, chicken pox, smallpox, Marburg virus, Lassa fever and African swine fever.
- 23. A method of treating a viral condition caused by an enveloped virus, said method comprising using a therapeutically effective amount of a compound selected from the group consisting of a substituted benzene, wherein said benzene comprises a 2-R.sup.1, 3-R.sup.2 -1-OX.sup.1, 4-OX.sup.2 compound where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring and wherein one of OX.sup.1 and OX.sup.2 is selected from the group consisting of hydroxy and oxo and the other is OR.sup.4 where R.sup.4 is a saturated or unsaturated hydrocarbon of less than four carbons.
- 24. A method of treating a viral condition caused by an enveloped virus, said method comprising using a therapeutically effective amount of a compound having an IC.sub.50 of less than 10.sup.-3 M in the INF assay, wherein said compound comprises a substituted benzene, wherein said benzene comprises a 2-R.sup.1, 3-R.sup.2 -1-OX.sup.1, 4-OX.sup.2 compound where at least one of R.sup.1 and R.sup.2 include a CH.sub.2 linkage to the benzene ring and wherein one of OX.sup.1 and OX.sup.2 is selected from the group consisting of hydroxy and oxo and the other is OR.sup.4 where R.sup.4 is a saturated or unsaturated hydrocarbon of less than four carbons.
- 25. A method of treating a viral condition wherein the viral condition is caused by a virus having a fusion protein which has a native, non-fusocienic conformation and a second, fusogenic conformation, the method comprising using a therapeutically effective amount of a compound which binds to the fusion protein in the native conformation and reduces the ability of the fusion protein to adopt the fusogenic conformation wherein said compound is a substituted benzene, comprising a 2-R.sup.1, 3-R.sup.2 -1-OX.sup.1, 4-OX.sup.2 compound where at least one of R.sup.1 and R.sup.2 include a carbon linkage to the benzene ring and wherein one of OX.sup.1 and OX.sup.2 is selected from the group consisting of hydroxy and oxo and the other is OR.sup.4 where R.sup.4 is a saturated or unsaturated hydrocarbon of less than four carbons.
- 26. The method of claim 1 wherein said compound is the tautomeric ene-dione form of said substituted benzene.
- 27. The method of claim 24 wherein said compound is the tautomeric ene-dione form of said substituted benzene.
- 28. The method of claim 25 wherein said compound is the tautomeric ene-dione form of said substituted benzene.
ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT
This invention was made in part with Government support under grant nos. GM-31497 and GM-39552 from the National Institutes of Health. The Government has certain rights in this invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4898891 |
Lavic et al. |
Feb 1990 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0923028 |
Feb 1983 |
SUX |